Cancer Stem Cell News Volume 2.07 | Feb 20 2013


    Cancer Stem Cell News 2.07 February 20, 2013
         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

    A Cancer Stem Cell Model for Studying Brain Metastases from Primary Lung Cancer
    Investigators applied previously developed primary solid tumor-initiating cell models to the study of brain metastases from the lung to evaluate the presence of a cancer stem cell population. [J Natl Cancer Inst] Abstract

    NeuroCult™ for Brain Tumor Research - View Publications

    PUBLICATIONS (Ranked by impact factor of the journal)

    Impact of Deleterious Passenger Mutations on Cancer Progression
    Cancer progression is driven by the accumulation of a small number of genetic alterations. However, these few driver alterations reside in a cancer genome alongside tens of thousands of additional mutations termed passengers. Researchers investigated the potential of moderately deleterious passengers to accumulate and alter the course of neoplastic progression. The results suggest a unique framework for understanding cancer progression as a balance of driver and passenger mutations. [Proc Natl Acad Sci USA]
    Abstract | Press Release

    Direct Reprogramming by Oncogenic Ras and Myc
    Scientists used a model of conditional expression of oncogenic KrasG12D allele in primary mouse cells to show that reprogramming and dedifferentiation is a fundamental early step in malignant transformation and cancer initiation. [Proc Natl Acad Sci USA] Abstract

    CD44-Positive Cancer Stem Cells Expressing Cellular Prion Protein Contribute to Metastatic Capacity in Colorectal Cancer
    Findings revealed the function of cellular prion protein (PrPc) in regulating epithelial to mesenchymal transition in cancer stem cells, and identified PrPc as candidate therapeutic target in metastatic colorectal cancer. [Cancer Res] Abstract | Full Article

    Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
    Findings demonstrated that STAT5A has a selective role in contributing to stress resistance through unconventional mechanisms, offering new opportunities to eradicate the most primitive and TKI- resistant chronic myeloid leukemia cells with an additional potential to eradicate persistent stem cell populations. [Cancer Res] Abstract

    Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma
    Cellular heterogeneity, e.g., the intratumoral coexistence of cancer cells with and without stem cell characteristics, represents a potential root of therapeutic resistance and a significant challenge for modern drug development in glioblastoma. Researchers proposed that activation of the innate immune system by stimulation of innate immune receptors involved in antiviral and antitumor responses can similarly target different malignant populations of glioma cells. [Stem Cells] Abstract

    Mesenchymal Stromal Cell Atrophy in Co-Culture Increases Aggressiveness of Transformed Cells
    Researchers showed that papillary thyroid cancer TPC1 and HEK 293T cells interact physically with human primary bone marrow-derived mesenchymal stromal cells (MSCs) followed by evanescence of MSC cytoplasm. The co-culture model system describes how adjacent transformed cells absorb stromal cells thereby leading to the stroma-driven evolution of moderately carcinogenic cells to highly aggressive metastatic cells. [Stem Cells] Abstract

    Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors
    This work resulted in the discovery of the 5-morpholino-7H-thieno[3,2-b]pyran-7-one system as the foundation of a new compound class of potential phosphatidylinositol-3-kinase (PI3K) inhibitors having improved potency towards PI3K. The synthesis and cancer stem cell-based activity of these compounds are reported. [J Med Chem] Abstract

    Krüppel-Like Factor 4 Acts as an Oncogene in Colon Cancer Stem Cell-Enriched Spheroid Cells
    Investigators found that culturing DLD-1 cells, one type of cells derived from colon cancers, in serum-free medium enriches cancer stem cells (CSCs) and the expression of Krüppel-like factor 4 (KLF4) is essential for the characteristics of CSCs in DLD-1. [PLoS One] Full Article

    FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

    Multiple Myeloma-Initiating Cells
    Distinct from acute myeloid leukemia-initiating cells, which are derived from undifferentiated stem or progenitor cells, multiple myeloma (MM)-initiating cells are derived from plasma cells, which are terminally differentiated cells. An improved understanding of how the bone marrow microenvironment supports MM-initiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model, is thus now essential. [Int J Hematol] Abstract

    Bionomics Provides BNC101 Update
    Bionomics Limited provided an update on the BNC101 LGR5 cancer program. As a result of Bionomics’ acquisition of Biogen Idec’s San Diego spinout Eclipse Therapeutics, Bionomics acquired ET-101, a cancer stem cell targeting antibody, now referred to as BNC101. [Press release from Bionomics Limited discussing research presented at the Molecular Med TriCON “Targeting Cancer Stem Cells” 2013 Meeting, San Francisco] Press Release


    CS-6 Highly Active against Ovarian Cancer Stem Cells
    Novogen announced the results of an important study concerning its lead experimental drug, CS-6. The study was designed to test the ability of the experimental anti-cancer drug, CS-6, to kill ovarian cancer stem cells. [Novogen Ltd] Press Release

    Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma
    Verastem, Inc. announced the filing of orphan drug designation for VS-6063. Verastem is seeking orphan drug designation in the US and the EU for the use of VS-6063 in mesothelioma. VS-6063 is an oral small molecule inhibitor of focal adhesion kinase, which is a critical pathway for cancer stem cells. [Verastem, Inc.] Press Release

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW Accelerating Anticancer Agent Development and Validation Workshop
    May 8-10, 2013
    Bethesda, United States

    our events page to see a complete list of events in the cancer stem cell community.


    Postdoctoral Fellow – Cancer Biology and Stem Cell (University of Texas at Houston, Medical School)

    Postdoctoral Fellow – Myeloproliferative Neoplasms (Mount Sinai Medical Center)

    Postdoctoral Fellow – Breast Cancer Stem Cells (University of Cincinnati College of Medicine)

    Faculties in Cancer Biology & Immunotherapy (Huzhou University School of Medicine)

    Postdoctoral Scientist (Eli Lilly)

    Postdoctoral Position (University of Kentucky College of Medicine)

    PhD Studentship Opportunity (University of East Anglia)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email with your feedback.

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us